Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.50 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 3/20 | 0.49 |
| ▸ | RAB9A | P51151 | 3/20 | 0.49 |
| ▸ | CES2 | O00748 | 2/20 | 0.49 |
| ▸ | CES1 | P23141 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | GSK3B | P49841 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Satigrel SCHEMBL9050447 | 0.98 | PDE4B (0.53) | PDE4BALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL9549165 | 0.94 | PDE4B (0.49) | PDE4BALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL9549159 | 0.94 | PDE4B (0.49) | PDE4BALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL9549180 | 0.94 | PDE4B (0.49) | PDE4BALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL9549204 | 0.93 | PDE4B (0.61) | PDE4BALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL9549325 | 0.92 | ALDH1A1 (0.49) | PDE4BALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL9549320 | 0.92 | ALDH1A1 (0.49) | PDE4BALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL9549067 | 0.88 | CA1 (0.49) | PDE4BALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL9549213 | 0.86 | PDE4B (0.53) | PDE4BALDH1A1CYP1A2HPGDCYP2C19 | |
| SCHEMBL9549205 | 0.86 | PDE4B (0.53) | PDE4BALDH1A1CYP1A2HPGDCYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 577 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1931320-B1 | MICROPARTICLES WITH MODIFIED RELEASE OF AT LEAST ONE ACTIVE PRINCIPLE AND ORAL DOSAGE FORM COMPRISING THE SAME | FLAMEL IRELAND LTD (IE) | 2022-06-15 | — | — | EP | claimed |
| EP-3998932-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | Parsons, C. Lowell (US) | 2022-05-25 | — | — | EP | claimed |
| WO-2021011566-A1 | ALKALIZATION OF URINARY BLADDER WALL PRIOR TO TREATMENT WITH INTRAVESICAL HEPARIN AND ALKALINIZED LIDOCAINE TO ENHANCE RELIEF OF BLADDER PAIN SYMPTOMS | PARSONS C LOWELL (US) | 2021-01-21 | — | — | WO | claimed |
| EP-3609483-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | Urigen Pharmaceuticals, Inc. (US) | 2020-02-19 | — | — | EP | claimed |
| WO-2018191412-A9 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2019-05-31 | — | — | WO | claimed |
| WO-2018191412-A1 | ARTICLE OF MANUFACTURE COMPRISING LOCAL ANESTHETIC, BUFFER, AND GLYCOSAMINOGLYCAN IN SYRINGE WITH IMPROVED STABILITY | URIGEN PHARMACEUTICALS, INC. (US) | 2018-10-18 | — | — | WO | claimed |
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | SATYAM APPARAO (IN) | 2015-11-19 | — | — | US | claimed |
| US-9040483-B2 | Controlled release compositions of agents that reduce circulating levels of platelets and methods therefor | BIOVASCULAR, INC. (US) | 2015-05-26 | — | — | US | claimed |
| US-9016221-B2 | Surface topographies for non-toxic bioadhesion control | UNIVERSITY OF FLORIDA RESEARCH FOUNDATION, INC. (US) | 2015-04-28 | — | — | US | claimed |
| WO-2014111957-A1 | NITRIC OXIDE RELEASING PRODRUGS OF THERAPEUTIC AGENTS | SATYAM APPARAO (IN) | 2014-07-24 | — | — | WO | claimed |
| US-20060018933-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| US-20060018934-A1 | Novel drug delivery system | TORRENT PHARMACEUTICALS LIMITED (IN) | 2006-01-26 | — | — | US | claimed |
| EP-0665023-B1 | MEDICAL MATERIAL AND PROCESS FOR PRODUCING THE SAME | OTSUKA PHARMA CO LTD (JP) | 2004-04-21 | — | — | EP | claimed |
| EP-1336602-A1 | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases | Scaramuzzino, Giovanni (IT) | 2003-08-20 | — | — | EP | claimed |
| US-5756553-A | Medical material and process for producing the same | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1998-05-26 | — | — | US | claimed |
| EP-0665023-A1 | MEDICAL MATERIAL AND PROCESS FOR PRODUCING THE SAME | OTSUKA PHARMACEUTICAL FACTORY, INC. (JP) | 1995-08-02 | — | — | EP | claimed |
| EP-0238973-B1 | DIPHENYL-METHANE DERIVATIVE, PHARMACEUTICAL COMPOSITION AND USE | Eisai Co., Ltd. (JP) | 1992-12-02 | — | — | EP | claimed |
| US-4978767-A | ANTICOAGULANTS | EISAI CO., LTD. (JP) | 1990-12-18 | — | — | US | claimed |
| US-4886834-A | ANTICOAGULANTS | EISAI CO., LTD. (JP) | 1989-12-12 | — | — | US | claimed |
| EP-0238973-A2 | Diphenyl-methane derivative, pharmaceutical composition and use | Eisai Co., Ltd. (JP) | 1987-09-30 | — | — | EP | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150328323-A1 | Nitric Oxide Releasing Produgs of Therapeutic Agents | NOS2, NOS1, PTGIS | PDE4B 61/4885ALDH1A1 291/4885CYP1A2 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.